TABLE 2.
The role of lncRNAs in retinoblastoma.
| LncRNA | Expression status | Target | Detection method | Effect | Model | Cell line | Reference |
|---|---|---|---|---|---|---|---|
| KCNQ1OT1 | Up | miR-124 | RT-qPCR | Increased proliferation, migration, and cell cycle, reduced apoptosis | Human 1 , in vitro, in vivo | Y79, WERI-RB1, hTERT RPE-1 | Zhang et al. (2021b) |
| Up | miR-134 | qRT-PCR | Promoted proliferation, migration and invasion | Human, in vitro, in vivo | WERI-RB1, Y79, ARPE-19 | Wang et al. (2021c) | |
| Up | miR-153-3p | qRT-PCR | Promoted proliferation, migration and invasion | Human, in vitro | SO-Rb50, HXO-RB44 | Wang et al. (2020a) | |
| XIST | Up | miR-140-5p | qRT-PCR | Promoted proliferation and invasion | Human, in vitro | ARPE-19, Y79, WERI-RB1, SO-Rb50, HXO-RB44 | Wang et al. (2020b) |
| Up | miR-142-5p | qRT-PCR | Promoted proliferation and epithelial-mesenchymal transition | Human, in vitro | WERI-RB1, HXO-RB44, SO-RB50, ARPE-19, Y79 | Xu and Tian, (2020) | |
| Up | miR-191-5p | qRT-PCR | Promoted proliferation, migration, invasion, and reduced apoptosis | Human, in vitro | HXO-RB44, WERI-RB-1, SO-RB50, ARPE-19, Y79 | Xu et al. (2021d) | |
| Up | miR-204-5p | qRT-PCR | Enhanced proliferation and autophagy, induced vincristine resistance | Human, in vitro, in vivo | WERI-RB1, Y79, ARPE-19 | Yao et al. (2020) | |
| Up | miR-200a-3p | qRT-PCR | Induced EMT, proliferation and invasion, inhibited apoptosis | Human, in vitro | Y79, ARPE-19 | Zhao et al. (2020b) | |
| Up | miR-361-3p | qRT-PCR | Promoted proliferation, migration, invasion and autophagy, suppressed apoptosis | In vitro, human, in vivo | Y79, WERI-RB1, ARPE-19 | Yang et al. (2020c) | |
| Up | miR-101 | RT-PCR | Promoted proliferation, migration, invasion and EMT, suppressed apoptosis, reduced caspase-3 activity | In vitro, human | SO-RB50, Y79, WERI-RB1, ARPE-19 | Cheng et al. (2019) | |
| FEZF1-AS1 | Up | miR-363-3p | qPCR | Promoted viability and proliferation, reduced apoptosis | Human, in vitro | WERI-RB1, Y79, ARPE-19 | Liu et al. (2021b) |
| Up | miR-1236-3p | RT-qPCR | Promoted EMT, migration and invasion | In vitro | ARPE-19, Y79, SO-Rb50, WERI-RB1, RBL-13 | Zhang et al. (2020d) | |
| UCA1 | Up | miR-513a-5p | qRT-PCR | Increased proliferation and multidrug resistance | Human, in vitro | SO-RB50, HEK-293T | Yang et al. (2020d) |
| LINC00858 | Up | miR-3182 | RT-qPCR | Promoted proliferation, migration and invasion | Human, in vitro | SO-RB50, Y79, HXO-RB44, WERI-RB1, ARPE-19 | Wang et al. (2020c) |
| LINC00152 | Up | MiR-613 | RT-qPCR | Increased aggressiveness; Enhanced carboplatin and adriamycin Resistance | Human, in vitro, in vivo | Y79, WERI-RB1, ARPE-19, RBL-13, SO-RB50 | Wang et al. (2020d) |
| LincRNA-ROR | Up | miR-32-5p | qRT-PCR | Correlated with optic nerve invasion, nodal or distant metastasis, and recurrence | Human, in vitro, in vivo | hTERT RPE-1, WERI-RB1, Y79 | Gao et al. (2021d) |
| MIAT | Up | miR-665 | RT-qPCR | Increased proliferation, migration and invasion | Human, in vitro | ARPE-19, HXO-RB44, WERI-RB1, SO-RB50, Y79 | Xu et al. (2021b) |
| CCAT1 | Up | miR-218-5p | Q-PCR | Promoted EMT, migration and invasion | Human, in vitro | SO-RB50, Y79, WERI-RB1, ARPE-19 | Meng et al. (2021) |
| Up | miR-218-5p | qRT-PCR | Promoted proliferation, migration and invasion, reduced apoptosis | In vitro | SO-RB50, Y79, WERI-RB1 | Zhang et al. (2017b) | |
| LINC00202 | Up | miR-204-5p | qRT-PCR | Promoted tumor progression by regulating proliferation, apoptosis and aerobic glycolysis | Human, in vitro, in vivo | Y79, HXO-RB44 | Wu et al. (2020) |
| Up | miR-3619-5p | qRT-PCR | Promoted proliferation, migration and invasion | In vitro, human | Y79, WERI-RB1, SORB50, hTERT-RPE1, ARPE-19, HXO-RB44 | Yan et al. (2019) | |
| SNHG20 | Up | miR-335-5p | RT-qPCR | Promoted proliferation, migration and invasion | Human, in vitro | WERI-RB1, SO-RB50, ARPE-19, Y79 | Song and Zhang, (2021) |
| SND1-IT1 | Up | miR-132-3p | RT-qPCR | Promoted proliferation, invasion and migration | Human, in vitro, in vivo | WERI-RB1, SO-RB50, ARPE-19, Y79 | Yin et al. (2021) |
| TMPO-AS1 | Up | miR-199a-5p | qRT-PCR | Promoted proliferation, migration and invasion | Human, in vitro | HXO-RB44, SO-Rb50 | Peng et al. (2020) |
| DANCR | Up | miR-34c, miR-613 | RT-PCR | Promoted proliferation, migration, invasion, and EMT, increased N-cadherin, vimentin) | Human, in vitro, in vivo | WERI-RB1, SO-RB50, Y79, HXO-RB44 | Wang et al. (2018b) |
| MBLN1-AS1 | Down | miR-338-5p | RT-qPCR | Inhibited Wnt/β-catenin signaling pathway, inhibited proliferation and migration | In vitro, in vivo | Y79, WERI-RB1, ARPE-19, SO-RB | Xu et al. (2021e) |
| HOTTIP | Up | miR-101-3p | qRT-PCR | Promoted proliferation, inhibited apoptosis | Human, in vitro, in vivo | Y79, HXO-RB-44, ARPE-19, SO-RB50 | Yuan et al. (2021) |
| HOTAIR | Up | miR-20b-5p | qRT-PCR | Promoted proliferation, inhibited apoptosis | In vivo, in vitro | ARPE-19, RPE-1, SORB50, Y79, HXO-RB44, WERI-RB1 | Fu et al. (2022) |
| ILF3-AS1 | Up | miR-132-3p | RT-qPCR | Enhanced proliferation and invasion | Human, in vitro, in vivo | ARPE-19, Y79, HXO-RB44, SO–Rb50, Rb1 | Han et al. (2020) |
| MALAT1 | Up | miR-124 | qRT-PCR | Induced proliferation, migration and invasion, inhibited apoptosis | In vitro | Y79, ARPE-19 | Liu et al. (2018e) |
| Up | miR-20b-5p | RT-qPCR | Promoted proliferation, suppressed apoptosis | In vitro, human, in vivo | SO-RB50, ARPE-19, HXO-RB44, WERI-RB1, Y79 | Wang et al. (2020e) | |
| LINC00205 | Up | microRNA-665 | RT-qPCR | Promoted proliferation, invasion and migration, reduced apoptosis, promoted tumor growth | Human, in vitro, in vivo | Y79, SO-RB50, WERI-RB1, ARPE-19 | Zhang et al. (2020b) |
| PVT1 | Up | miR-488-3p | qRT-PCR | Induced proliferation, migration, invasion, and cell cycle progression, inhibited apoptosis | Human, in vitro, in vivo | SO-RB50, WERI-RB1, Y79, HXO-RB44, ARPE-19 | Wu et al. (2019b) |
| H19 | Down | miR-17–92 | qRT-PCR | Inhibited proliferation, induced cell cycle arrest and apoptosis | Human, in vitro | ARPE-19, Y79, WERI-RB1, SO-RB50 | Zhang et al. (2018d) |
| MIR17HG | Up | miR-155-5p | qRT-PCR | Promoted proliferation, migration, and invasion | Human, in vitro | HXO-RB44, SO-Rb50, Y79, WERI-RB1, ARPE-19 | Yan et al. (2022) |
| PROX1-AS1 | Up | miR-519d-3p | − | Induced drug resistance, proliferation, migration and invasion, inhibited apoptosis | Human, in vitro | − | Chen et al. (2021b) |
| MIR7-3HG | Up | miR-27a-3p | qRT-PCR | Promoted proliferation, suppressed apoptosis | In vitro, human | Y79, WERI-RB1, ARPE-19 | Ding et al. (2020) |
| TP53TG1 | Up | miR-33b | qPCR | Promoted proliferation, migration and invasion | In vitro, human, in vivo | SO-RB50, WERI-RB1, Y79, RBL-13, ARPE-19 | Wang et al. (2021d) |
| FOXD2-AS1 | Up | miR-31 | qRT-PCR | Inhibited proliferation and migration | In vitro, human | SO-RB50, Y79, WERI-RB1, ARPE-19 | Liang et al. (2022a) |
| CASC9 | Up | miR-145-5p | qRT-PCR | Promoted proliferation, invasion and EMT, suppressed apoptosis | In vitro, human | Y79, WERI-RB1, ARPE-19 | Zhang et al. (2020c) |
| RHPN1-AS1 | Up | miR-3133 | qRT-PCR | Promoted viability, suppressed apoptosis | In vitro | Y79, WERI-RB1, ARPE-19 | Li et al. (2020d) |
| TP73-AS1 | Up | miR-139-3p | RT-qPCR | Promoted proliferation | In vitro, human | WERI-RB1, Y79 | Xia et al. (2019b) |
| ANRIL | Up | miR-328 | qRT-PCR | Increased resistance to DDP, proliferation, upregulated ABCG2 and MDR1, inhibited apoptosis | In vitro | HXO-RB44, Y79 | Yin et al. (2020) |
| ZFPM2-AS1 | Up | miR-515 | qRT-PCR | Promoted proliferation and metastasis, activated Wnt/β-catenin signaling | In vitro, in vivo, human | WERI-RB1, SO-RB50, Y79, ARPE-19 | Lyv et al. (2020) |
| Up | miR-511-3p | qRT-PCR | Promoted viability and migration | In vitro, human | SO-RB50, WERI-RB1, HXO-RB44, Y79, ARPE-19 | Ni et al. (2022) | |
| HCP5 | Up | miR-3619-5p | RT-qPCR | Promoted proliferation, migration and invasion | In vitro, in vivo, human | Y79, WERI-RB1, HXO-RB44, ARPE-19, SO-RB50 | Zhu and Hao, (2021) |
| LINC00324 | Up | miR-769-5p | RT-qPCR | Promoted proliferation, colony formation, migration and invasion, suppressed apoptosis | In vitro, in vivo, human | Y79, SO-RB50, WERI-RB1, ARPE-19 | Dong et al. (2020) |
| FTX | Up | miR-320a | qRT-PCR | Exacerbated aggressive phenotype, promoted proliferation, migration and invasion, promoted RB tumor growth | In vitro, in vivo, human | Y79, SO-RB50, WERI-RB1, ARPE-19 | Wang et al. (2021e) |
| LINC00488 | Up | miR-30a-5p | RT-qPCR | Increased tumorigenicity and malignant phenotype | Human, In vivo, In vitro | SO-RB-50, WERI-RB1, ARPE-19, Y79 | Cui et al. (2022) |
| NEAT1 | Up | miR-204 | -RT-PCR | Increased proliferation and migration, decreased apoptosis | In vitro, in vivo, human | Y79, WERI-RB1, SO‐RB50, ARPE‐19 | Zhong et al. (2019) |
| TUG1 | Up | − | qPCR | Promoted proliferation, migration, invasion, and induced EMT | Human, in vitro | WERI-RB1, Y79, SO-RB50, RBL-13, ARPE-19 | Wang et al. (2022) |
Human; RB samples obtained from patients.